Last edition
News about "CAR-T therapies "
Johnson & Johnson Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies
Johnson & Johnson has entered into a collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases that includes a USD 465 million equity investment, milestone-based payments and an exclusive option to acquire Sail Biomedicines for USD 2.58 billion.
CAR-T Therapies | 31/07/2026 | By News Bureau | 102
Cellipont Bioservices and Adva Biotechnology Unveil ADVA X3 Platform
Cellipont Bioservices has joined hands with Adva Biotechnology, marking the launch of the groundbreaking ADVA X3 platform in North America.
CAR-T Therapies | 09/05/2024 | By Aishwarya | 705
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy